abstract |
The invention provides the use of Babaodan in the preparation of a medicament for treating cisplatin-resistant gastric cancer. The study found that different concentrations of Babaodan can significantly inhibit the growth, migration, invasion and adhesion of DDP-resistant gastric cancer cells, inhibit the growth and metastasis of gastric cancer-resistant SGC7901/DDP cells, and reduce their resistance to DDP. Therefore, Babaodan can be used for the treatment of DDP-resistant gastric cancer. |